Page last updated: 2024-11-05

shikimic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Shikimic acid is a naturally occurring organic compound found in a variety of plants, including star anise. It is a key intermediate in the biosynthesis of aromatic amino acids, such as phenylalanine, tyrosine, and tryptophan. These amino acids are essential building blocks for proteins and other important biomolecules. Shikimic acid has gained significant attention due to its role in the synthesis of oseltamivir (Tamiflu), an antiviral drug used to treat influenza infections. The synthesis of shikimic acid involves a complex metabolic pathway known as the shikimate pathway. This pathway is absent in animals, making it a target for the development of selective inhibitors of bacterial and parasitic growth. In addition to its importance in drug discovery, shikimic acid has also been investigated for its potential therapeutic properties, including antioxidant, anti-inflammatory, and anticancer activities. The compound's unique structure and biological activity continue to make it a subject of ongoing research.'

Shikimic Acid: A tri-hydroxy cyclohexene carboxylic acid important in biosynthesis of so many compounds that the shikimate pathway is named after it. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

shikimic acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid substituted by hydroxy groups at positions 3, 4 and 5 (the 3R,4S,5R stereoisomer). It is an intermediate metabolite in plants and microorganisms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8742
CHEMBL ID290345
CHEBI ID16119
SCHEMBL ID43377
MeSH IDM0019775

Synonyms (99)

Synonym
smr001306700
MLS002207031
[3r-(3alpha,4alpha,5beta)]-3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid
3alpha,4alpha,5beta-trihydroxy-1-cyclohexene-1-carboxylic acid
CHEBI:16119 ,
l-shikimic acid
DIVK1C_006584
KBIO1_001528
SDCCGMLS-0066740.P001
einecs 205-334-2
nsc 59257
1-cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3r-(3alpha,4alpha,5beta))-
(3r,4s,5r)-3,4,5-trihydroxycyclohex-1-enecarboxylic acid
SPECTRUM4_001853
SPECTRUM_001232
(3r,4s,5r)-3,4,5-trihydroxycyclohex-1-ene-1-carboxylic acid
MEGXP0_001939
BSPBIO_002982
hsdb 3537
shikimic acid [3r-(3alpha,4alpha,5beta)]-3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid
1-cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3r-(3alpha,4alpha,5beta))
1-cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3r,4s,5r)- (9ci)
1-cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3r,4s,5r)-
(3r,4s,5r)-(-)-3,4,5-trihydroxy-1-cyclohexenecarboxylic acid
ccris 7681
(-)-shikimic acid
(-)-3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid
inchi=1/c7h10o5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1,4-6,8-10h,2h2,(h,11,12)/t4-,5-,6-/m1/s
shikimic acid
138-59-0
C00493
SHIKIMATE ,
3,4,5-trihydroxy-1-cyclohexenecarboxylic acid
SR-01000632403-1
shikimic acid, >=99%
2AAY
1WE2
2AA9
SPECTRUM5_000386
SMP1_000326
NCGC00142601-01
KBIO2_004280
KBIO3_002482
KBIOSS_001712
KBIO2_006848
KBIOGR_002287
KBIO2_001712
SPECPLUS_000488
SPBIO_001555
SPECTRUM3_001541
SPECTRUM2_001508
SPECTRUM1502256
NCGC00142601-02
B1A53F8A-8664-405D-8370-A9785ADD2D0B
CHEMBL290345 ,
shicimic acid
(3r,4s,5r)-3,4,5-trihydroxycyclohexene-1-carboxylic acid
1-cyclohexene-1-carboxylic acid, 3,4,5-trihydroxy-, (3r-(3alpha,4alpha,5beta))- (9ci)
BMSE000114
(3r,4s,5r)-(-)-3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid
bdbm50281998
AKOS004119897
29ms2wi2nu ,
ec 205-334-2
unii-29ms2wi2nu
(4s,3r,5r)-3,4,5-trihydroxycyclohex-1-enecarboxylic acid
l-(-)-shikimic acid
c7h10o5
CCG-38884
MLS004256600
4GUJ
(-)-shikimate
(3r,4s,5r)-3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid
shikimic acid [iarc]
shikimic acid (constituent of cranberry liquid preparation) [dsc]
shikimic acid [hsdb]
shikimic acid [inci]
verochic
shikimic acid [mi]
SCHEMBL43377
Q-100148
DTXSID4032039
shikimic acid, analytical standard
SR-01000632403-5
SR-01000632403-4
sr-01000632403
AC-8010
skikimate
l-shikimate
hydrotris(3-phenylpyrazol-1-yl)borate thallium salt
(3r,4s,5r)-3,4,5-trihydroxycyclohexene-1-carboxylicacid
106210-02-0
CS-0007856
HY-N0130
Q410830
AS-13905
EN300-208879
[3r-(3 alpha,4 alpha,5 beta)]-3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid
Z1198149969

Research Excerpts

Overview

Shikimic acid (SA) is a valuable compound found in water hyacinth. It is a precursor for synthesis of antiviral drug oseltamivir phosphate (Tamiflu®) which is used to treat H5N1 avian influenza. Shikimi acid is an intermediate metabolite in the synthesis of aromatic amino acids in Escherichia coli.

ExcerptReferenceRelevance
"Shikimic acid (SA) is a valuable compound found in water hyacinth and is a precursor for synthesis of antiviral drug oseltamivir phosphate (Tamiflu®) which is used to treat H5N1 avian influenza. "( Extraction of shikimic acid from water hyacinth (Eichhornia crassipes) using sonication: An approach towards waste valorization.
Desai, MA; Ganorkar, PV; Jadeja, GC, 2022
)
2.52
"Shikimic acid is an intermediate metabolite in the synthesis of aromatic amino acids in Escherichia coli and a synthetic precursor of Tamiflu. "( [Using dynamic molecular switches for shikimic acid production in Escherichia coli].
Chen, X; Gao, C; Hou, J; Liu, L, 2020
)
2.27
"Shikimic acid is a intermediate of aromatic amino acid biosynthesis and the preferred starting material for production of the most commonly prescribed anti-influenza drug, Tamiflu. "( Novel comprehensive multidimensional liquid chromatography approach for elucidation of the microbosphere of shikimate-producing Escherichia coli SP1.1/pKD15.071 strain.
Cacciola, F; Cortes, HJ; Donato, P; Dugo, P; Mangraviti, D; Mondello, L; Rigano, F, 2018
)
1.92
"Shikimic acid is an important intermediate for the manufacture of the antiviral drug oseltamivir (Tamiflu®) and many other pharmaceutical compounds. "( Metabolic engineering strategies for enhanced shikimate biosynthesis: current scenario and future developments.
Bilal, M; Hu, H; Iqbal, HMN; Wang, S; Wang, W; Zhang, X; Zhao, Y, 2018
)
1.92
"Shikimic acid is a cyclohexanecarboxylic acid, reported to exhibit pharmacological properties including anti-inflammatory and antioxidant activities."( Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Cao, L; Chen, X; Li, X; Qin, L; Su, J; Zhai, X; Zhi, X, 2018
)
2.64
"Shikimic acid is an industrially important chiral compound used as a key ingredient in formulation of drug Oseltamivir phosphate (Tamiflu) for the treatment of swine/avian flu. "( Expanding horizons of shikimic acid. Recent progresses in production and its endless frontiers in application and market trends.
Rawat, G; Saxena, RK; Tripathi, P, 2013
)
2.15
"Shikimic acid (SA) is a key chiral starting molecule for the synthesis of the neuramidase inhibitor GS4104 against viral influenza. "( Metabolic flux responses to genetic modification for shikimic acid production by Bacillus subtilis strains.
Ai, GM; Jiang, CY; Liu, C; Liu, DF; Liu, LX; Liu, SJ; Liu, YM; Yang, C; Zhang, B; Zheng, QX, 2014
)
2.09
"Shikimic acid (SA) is an important intermediate in the synthesis of aromatic amino acids and has emerged as a key chiral starting material for the synthesis of antiviral drug oseltamivir phosphate (Tamiflu). "( [Improvements of shikimic acid production in Escherichia coli with ideal metabolic modification in biosynthetic pathway--a review].
Shi, G; Xiao, M; Zhang, L, 2014
)
2.18
"Shikimic acid (SA) is an industrially important chiral compound used in diverse commercial applications, and the insufficient supply by isolation from plants and expensive chemical synthesis of SA has increased the importance of developing strategies for SA synthesis. "( Recombinant expression of glpK and glpD genes improves the accumulation of shikimic acid in E. coli grown on glycerol.
Dou, J; Fang, H; Han, X; Wang, H; Yang, Y; Yuan, C; Zhou, C, 2014
)
2.08
"Shikimic acid is a suitable biomarker for a glyphosate exposure in coffee, using only young leaves for the analysis."( Glyphosate spray drift in Coffea arabica - sensitivity of coffee plants and possible use of shikimic acid as a biomarker for glyphosate exposure.
Cedergreen, N; Schrübbers, LC; Sørensen, JC; Valverde, BE, 2014
)
1.34
"Shikimic acid is a key intermediate in the aromatic amino acid pathway as well as an important starting material for the synthesis of Tamiflu, a potent and selective inhibitor of the neuraminidase enzyme of influenza viruses A and B. "( Regulation of primary metabolic pathways in oyster mushroom mycelia induced by blue light stimulation: accumulation of shikimic acid.
Kimura, N; Kojima, M; Miura, R, 2015
)
2.07
"The shikimic acid (SA) pathway is a fundamental route to synthesize aromatic building blocks for cell growth and metabolic processes, as well as for fermentative production of various aromatic compounds. "( Ribosome binding site libraries and pathway modules for shikimic acid synthesis with Corynebacterium glutamicum.
Jiang, CY; Liu, C; Liu, SJ; Liu, YM; Lou, CB; Zhang, B; Zhou, N, 2015
)
1.22
"Shikimic acid is an important metabolic intermediate with various applications. "( Improvement of shikimic acid production in Escherichia coli with growth phase-dependent regulation in the biosynthetic pathway from glycerol.
Hung, WP; Lee, MY; Tsai, SH, 2017
)
2.25
"Shikimic acid is a key intermediate for the synthesis of the antiviral drug oseltamivir (Tamiflu®). "( Production of shikimic acid.
Banerjee, UC; Chisti, Y; Ghosh, S,
)
1.93
"Shikimic acid (SA) is an important metabolic intermediate with diverse commercial applications. "( Deletion of the aroK gene is essential for high shikimic acid accumulation through the shikimate pathway in E. coli.
Chen, K; Dou, J; Fang, H; Tang, S; Wang, H; Yang, Y; Zhou, C, 2012
)
2.08
"Shikimic acid is a high valued compound used as a key starting material for the synthesis of the neuramidase inhibitor GS4104, which was developed under the name Tamiflu for treatment of antiviral infections. "( Metabolic engineering for microbial production of shikimic acid.
Bongaerts, J; Bovenberg, R; Krämer, M; Kremer, S; Müller, U; Orf, S; Raeven, L; Wubbolts, M, 2003
)
2.01
"1. Shikimic acid was shown to be a precursor of vitamin K(2) (MK-8) in Escherichia coli. "( The role of shikimic acid in the biosynthesis of vitamin K2.
Cox, GB; Gibson, F, 1966
)
1.24

Effects

Shikimic acid (SA) has wide use in pharmaceuticals due to its application in the synthesis of drug Tamiflu used in the treatment of Swine flu. SA has been reported to possess antibacterial activity against Staphylococcus aureus. The mode of action of SA is still elusive.

ExcerptReferenceRelevance
"Shikimic acid (SA) has recently been found to be a major component of plant stem cells. "( Shikimic acid, a mannose bioisostere, promotes hair growth with the induction of anagen hair cycle.
Choi, HI; Choi, M; Choi, SJ; Hwang, ST; Jang, S; Kang, BM; Kwon, O, 2019
)
3.4
"Shikimic acid (SA) has been mainly used in the pharmaceutical industry for production of drugs, however, recently it has also appeared in the world of cosmetics. "( Shikimic acid in the light of current knowledge.
Batory, M; Rotsztejn, H, 2022
)
3.61
"Shikimic acid has wide use in pharmaceuticals due to its application in the synthesis of drug Tamiflu used in the treatment of Swine flu. "( A natural isolate producing shikimic acid: isolation, identification, and culture condition optimization.
Jahan, F; Rawat, G; Saxena, RK; Tripathi, P, 2013
)
2.13
"Shikimic acid (SA) has been reported to possess antibacterial activity against Staphylococcus aureus, whereas the mode of action of SA is still elusive. "( Antibacterial Activity of Shikimic Acid from Pine Needles of Cedrus deodara against Staphylococcus aureus through Damage to Cell Membrane.
Bai, J; Gao, H; Huang, Y; Liu, X; Wu, Y; Zhong, K, 2015
)
2.16
"Shikimic acid has various pharmaceutical and industrial applications. "( Studies on the production of shikimic acid using the aroK knockout strain of Bacillus megaterium.
Banerjee, UC; Ghosh, S; Mohan, U, 2016
)
2.17
"Shikimic acid has been described as a potent competitive inhibitor of the activity of C4 phosphoenolpyruvate carboxylase (PEPC) from Amaranthus viridis. "( The interaction of shikimic acid and protein phosphorylation with PEP carboxylase from the C4 dicot Amaranthus viridis.
Andreo, CS; Chollet, R; Colombo, SL, 1998
)
2.07

Actions

ExcerptReferenceRelevance
"Shikimic acid, reported to cause tumors in mice, and its close structural analog, quinic acid, both ubiquitous constituents of higher plants, were found not be be mutagenic in the Ames assay when tested with and without the rat liver microsomal activation system."( Shikimic acid and quinic acid are not mutagenic in the Ames assay.
Floss, HG; Jacobsen, LB; Richardson, CL,
)
3.02

Toxicity

ExcerptReferenceRelevance
"Bracken fern (Pteridium aquilinum) causes acute and chronic toxicity in animals and is associated with a high incidence of stomach and esophageal tumors in humans in countries where it is consumed as food, yet the toxic constituent(s) has not been unequivocally identified."( Genotoxicity studies of quercetin and shikimate in vivo in the bone marrow of mice and gastric mucosal cells of rats.
Jones, RS; Ngomuo, AJ, 1996
)
0.29
" The engineered NPTII and CP4 EPSPS proteins were heat-labile, readily digestible, and according to the bioinformatics analyses, unlikely to cause an allergenic or toxic reaction in humans or animals."( Safety Assessment of the CP4 EPSPS and NPTII Proteins in Eucalyptus.
Avisar, D; Azulay, S; Bombonato, L; Carvalho, D; Dallapicolla, H; de Souza, C; Dias, T; Dos Santos, A; Galan, MP; Galvao, M; Gonsalves, JM; Gonzales, E; Graça, R; Livne, S; Mafia, R; Manoeli, A; May, M; Menezes, TRD; Pinheiro, AC; Porto, A; Rocha, C; Schafer, A; Schafer, B; Silva, W; Zauza, E, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"1 microgram/ml, suggesting that the negative in vivo results may have been due to limited bioavailability of the compound."( Genotoxicity studies of quercetin and shikimate in vivo in the bone marrow of mice and gastric mucosal cells of rats.
Jones, RS; Ngomuo, AJ, 1996
)
0.29
" The intestinal absorption rate was not enhanced with increasing drug concentration (5-15 μg/mL) which suggested that active transport or facilitated diffusion could play vital role in SA absorption."( Reduced Burst Release and Enhanced Oral Bioavailability in Shikimic Acid-Loaded Polylactic Acid Submicron Particles by Coaxial Electrospray.
Omari-Siaw, E; Wang, M; Wang, S; Wang, Y; Xu, X; Zhu, Y, 2016
)
0.68
" Bioavailability of Haritaki Churna is very high in digestive track and treatment of colorectal cancer cells HCT-116, DLD1, HT-29 with HCAE reduces its cellular viability with anti-cancer IC50 70μg/ml."( Extraction, phytochemical characterization and anti-cancer mechanism of Haritaki churna: An ayurvedic formulation.
Khan, MRUZ; Trivedi, V; Yanase, E, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
"Groups of male Alderly Park mice of proven fertility were dosed by gavage for 5 consecutive days per week for 8 weeks or 5 consecutive days only with 100 or 150 mg/kg body weight ethyl methanesulphonate (EMS) or by intraperitoneal injection once a week for 8 weeks or once only with 500 mg/kg shikimic acid."( Comparison of dominant lethal and heritable translocation methodologies.
Anderson, D; Hodge, MC; Palmer, S; Purchase, IF, 1981
)
0.44
" This direct comparison conclusively confirms that horseweed plants collected in western Tennessee in 2002 are resistant to 4 times the normal application dosage of glyphosate."( Shikimate accumulates in both glyphosate-sensitive and glyphosate-resistant horseweed (Conyza canadensis L. Cronq.).
Hayes, RM; Main, CL; Massey, JH; Mueller, TC; Stewart, CN, 2003
)
0.32
" Based on a Petri dish dose-response bioassay, the OR and the SF populations were two and fivefold more resistant to glyphosate when compared to the susceptible (S) population, respectively; however, based on a whole-plant dose-response bioassay, both OR and SF populations were fivefold more resistant to glyphosate than the S population, implying that different resistance mechanisms might be involved."( Investigating the mechanisms of glyphosate resistance in Lolium multiflorum.
Colquhoun, J; Mallory-Smith, CA; Park, KW; Perez-Jones, A; Polge, N, 2007
)
0.34
" Dose-response assays were conducted to characterize the extreme populations further, and shikimate accumulation in vivo was determined using a spectrophotometric method."( Response of wild Brassica juncea populations to glyphosate.
Huangfu, CH; Qiang, S; Song, XL; Zhang, HJ, 2007
)
0.34
" Dose-response experiments indicated a glyphosate tolerance ratio [ED(50)(C."( Nontarget mechanims involved in glyphosate tolerance found in Canavalia ensiformis plants.
Cruz-Hipolito, H; De Prado, R; Heredia, A; Osuna, MD; Ruiz-Santaella, JP, 2009
)
0.35
" Dose-response experiments yielded ED50 values (50% effect dose) in the range of 38-550 ga."( Glyphosate spray drift in Coffea arabica - sensitivity of coffee plants and possible use of shikimic acid as a biomarker for glyphosate exposure.
Cedergreen, N; Schrübbers, LC; Sørensen, JC; Valverde, BE, 2014
)
0.62
" Dose-response assays confirmed resistance in seven different accessions."( First confirmation and characterization of target and non-target site resistance to glyphosate in Palmer amaranth (Amaranthus palmeri) from Mexico.
Alcántara-de la Cruz, R; Cruz-Hipolito, HE; De Prado, R; Dominguez-Valenzuela, JA; Fernández-Moreno, PT; Gherekhloo, J; Sánchez-González, E, 2017
)
0.46
" Dose-response and shikimate accumulation assays confirmed resistance of the resistant (R) biotypes."( Pro-106-Ser mutation and EPSPS overexpression acting together simultaneously in glyphosate-resistant goosegrass (Eleusine indica).
Alcántara-de la Cruz, R; Cruz-Hipolito, HE; De Prado, R; Domínguez-Valenzuela, JA; Fernández-Moreno, PT; Gherekhloo, J; Sánchez-González, E, 2017
)
0.46
" Data obtained by the study indicated that the medium selection and pH control were important for liquid preparation of ISA, and avoiding dissolution and absorption in stomach was critical for the oral solid dosage forms."( Preformulation study and initial determination of biological Properties of isopropylidene shikimic acid.
Kong, H; Lin, L; Ni, J; Qu, C; Wu, H; Yang, P; Yin, X; Zhang, H; Zhang, X, 2018
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
cyclohexenecarboxylic acid
hydroxy monocarboxylic acidAny monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent.
alpha,beta-unsaturated monocarboxylic acidA monocarboxylic acid in which the carbon of the carboxy group is directly attached to a C=C or C#C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Chorismate Biosynthesis1017
Secondary Metabolites: Shikimate Pathway811
Shikimate Pathway (Chorismate Biosynthesis)716
Flavonoid Biosynthesis1150
Stilbenoid, Diarylheptanoid, and Gingerol Biosynthesis417
Phenylalanine, tyrosine, and tryptophan biosynthesis012
Mycobacterium tuberculosis biological processes3962
Chorismate via Shikimate Pathway721
AtMetExpress overview0109
shikimate pathway315
Lignin biosynthesis221

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.35480.003245.467312,589.2998AID2517
gemininHomo sapiens (human)Potency2.48860.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferaseEscherichia coliIC50 (µMol)1,200.00001,200.00001,200.00001,200.0000AID977608
Chain A, 3-phosphoshikimate 1-carboxyvinyltransferaseEscherichia coliIC50 (µMol)1,200.00001,200.00001,200.00001,200.0000AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Shikimate kinaseMycobacterium tuberculosisKd44.000044.000044.000044.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID280290Inhibition of human E-selectin after 2 hrs at 100 uM2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID280294Inhibition of human L-selectin after 2 hrs at 100 uM2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID280292Inhibition of human P-selectin after 2 hrs at 100 uM2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID280296Inhibition of attachment of HL60 cells to P-selectin at 109 uM after 5 mins2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID280295Inhibition of attachment of HL60 cells to E-selectin at 109 uM after 5 mins2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID336478Inhibition of COX2 at 100 uM by scintillation proximity assay2002Journal of natural products, Nov, Volume: 65, Issue:11
Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2005FEBS letters, Oct-24, Volume: 579, Issue:25
Molecular basis for the glyphosate-insensitivity of the reaction of 5-enolpyruvylshikimate 3-phosphate synthase with shikimate.
AID1811Experimentally measured binding affinity data derived from PDB2005FEBS letters, Oct-24, Volume: 579, Issue:25
Molecular basis for the glyphosate-insensitivity of the reaction of 5-enolpyruvylshikimate 3-phosphate synthase with shikimate.
AID1811Experimentally measured binding affinity data derived from PDB2004Acta crystallographica. Section D, Biological crystallography, Dec, Volume: 60, Issue:Pt 12 Pt 2
Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004Acta crystallographica. Section D, Biological crystallography, Dec, Volume: 60, Issue:Pt 12 Pt 2
Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2014Biochemistry, Feb-11, Volume: 53, Issue:5
Crystal structures of type I dehydroquinate dehydratase in complex with quinate and shikimate suggest a novel mechanism of Schiff base formation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,130)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990306 (27.08)18.7374
1990's92 (8.14)18.2507
2000's220 (19.47)29.6817
2010's356 (31.50)24.3611
2020's156 (13.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.46 (24.57)
Research Supply Index7.07 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index103.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.17%)5.53%
Reviews98 (8.36%)6.00%
Case Studies1 (0.09%)4.05%
Observational1 (0.09%)0.25%
Other1,070 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]